Abstract
Since stem cell-derived cardiomyocytes will potentially play an important role in safety evaluations and drug screening in the future, we investigated cells from different stem cell suppliers with a new label-free technique based on impedance analysis. The used platform, called the CardioExcyte 96, allows precise impedance measurements at a time resolution of 1 ms and generates 96 recordings in parallel.Stem cells from GE Healthcare, Axiogenesis and Cellectis were successfully tested and data will be compared. Dose response curves or single-point screening experiments of several drugs (e.g. hERG and Cav1.2 blockers) were collected and will be presented. The capability of the data analysis software of the CardioExcyte 96 platform allows for a time effective analysis of data sets due to it's features and ease-of-use. The presented data will show that the CardioExcyte 96 and the corresponding CardioExcyte Control software can be used efficiently to predict drug-induced arrhythmia for cardiac risk assessment.View Large Image | View Hi-Res Image | Download PowerPoint Slide
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call